Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production

Journal of Bone and Mineral Research

Volumn 26, Issue 4, 2011, Pages 761-768

  Courtland, Hayden William ^a   Sun, Hui ^a   Beth On, Mordechay ^a   Wu, Yingjie ^a   Elis, Sebastien ^a   Rosen, Clifford J ^b   Yakar, Shoshana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

bone; endocrine; IGF 1; LID mice; mechanical properties; micro computed tomography

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; PEGVISOMANT; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; BONE DEVELOPMENT; BONE GROWTH; CONTROLLED STUDY; FEMUR; GENE EXPRESSION; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; LIVER; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PUBERTY; TISSUE SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ANIMALS; BODY COMPOSITION; BODY WEIGHT; BONE DEVELOPMENT; CARRIER PROTEINS; FEMUR; GENE EXPRESSION; GLYCOPROTEINS; GROWTH HORMONE; HUMAN GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; MECHANICAL PROCESSES; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; OSTEOCALCIN; OSTEOGENESIS; PUBERTY;

EID: 79953033748     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.265     Document Type: Article

References (32)

1. He J, Rosen CJ, Adams DJ, Kream BE,. Postnatal growth and bone mass in mice with IGF-1 haploinsufficiency. Bone. 2006; 38: 826-835. (Pubitemid 44498595)
2. Mohan S, Baylink DJ,. Impaired skeletal growth in mice with haploinsufficiency of IGF-1: genetic evidence that differences in IGF-1 expression could contribute to peak bone mineral density differences. J Endocrinol. 2005; 185: 415-420. (Pubitemid 40883386)
3. Powell-Braxton L, Hollingshead P, Giltinan D, Pitts-Meek S, Stewart T,. Inactivation of the Igf1 gene in mice results in perinatal lethality. Ann NY Acad Sci. 1993; 692: 300-301. (Pubitemid 23299551)
4. Yakar S, Canalis E, Sun H, Mejia W, et al. Serum IGF-1 determines skeletal strength by regulating sub-periosteal expansion and trait interactions. J Bone Miner Res. 2009.
5. Sjogren K, Bohlooly YM, Olsson B, et al. Disproportional skeletal growth and markedly decreased bone mineral content in growth hormone receptor -/- mice. Biochem Biophys Res Commun. 2000; 267: 603-608. (Pubitemid 30076845)
6. Scillitani A, Battista C, Chiodini I, et al. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin Endocrinol (Oxf). 2003; 58: 725-731. (Pubitemid 36702732)
7. Vestergaard P, Mosekilde L,. Fracture risk is decreased in acromegaly - a potential beneficial effect of growth hormone. Osteoporos Int. 2004; 15: 155-159. (Pubitemid 38258315)
8. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA,. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997; 137: 240-245. (Pubitemid 27405107)
9. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001; 16: 398-405. (Pubitemid 32106717)
10. Holmer H, Svensson J, Rylander L, et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res. 2007; 22: 1842-1850. (Pubitemid 351229300)
11. Harding PA, Wang X, Okada S, Chen WY, Wan W, Kopchick JJ,. Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem. 1996; 271: 6708-6712. (Pubitemid 26104101)
12. Ross RJ, Leung KC, Maamra M, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab. 2001; 86: 1716-1723. (Pubitemid 32374928)
13. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000; 342: 1171-1177. (Pubitemid 30211048)
14. Fairfield WP, Sesmilo G, Katznelson L, et al. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf). 2002; 57: 385-390. (Pubitemid 35013819)
15. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ,. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab. 2003; 88: 5650-5655. (Pubitemid 38033029)
16. van Neck JW, Dits NF, Cingel V, Hoppenbrouwers IA, Drop SL, Flyvbjerg A,. Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice. J Endocrinol. 2000; 167: 295-303.
17. Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J,. Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology. 2006; 147: 3877-3888. (Pubitemid 44079393)
18. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002; 110: 771-781.
19. Yakar S, Bouxsein ML, Canalis E, et al. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol. 2006; 189: 289-299.
20. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004; 113: 96-105. (Pubitemid 38541636)
21. Jepsen KJ, Hu B, Tommasini SM, et al. Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility. Mamm Genome. 2007; 18: 492-507. (Pubitemid 47360414)
22. Jepsen KJ, Pennington DE, Lee YL, Warman M, Nadeau J,. Bone brittleness varies with genetic background in A/J and C57BL/6J inbred mice. J Bone Miner Res. 2001; 16: 1854-1862. (Pubitemid 32911492)
23. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
24. Jepsen KJ, Schaffler MB, Kuhn JL, Goulet RW, Bonadio J, Goldstein SA,. Type I collagen mutation alters the strength and fatigue behavior of Mov13 cortical tissue. J Biomech. 1997; 30: 1141-1147. (Pubitemid 28026503)
25. Wolf E, Wanke R, Schenck E, Hermanns W, Brem G,. Effects of growth hormone overproduction on grip strength of transgenic mice. Eur J Endocrinol. 1995; 133: 735-740. (Pubitemid 26017317)
26. Sotiropoulos A, Ohanna M, Kedzia C, et al. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proc Natl Acad Sci U S A. 2006; 103: 7315-7320. (Pubitemid 43727830)
27. King D, Jarjoura D, McEwen HA, Askew MJ,. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta. J Bone Miner Res. 2005; 20: 987-993. (Pubitemid 40712823)
28. DiGirolamo DJ, Mukherjee A, Fulzele K, et al. Mode of growth hormone action in osteoblasts. J Biol Chem. 2007; 282: 31666-31674. (Pubitemid 350044902)
29. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A,. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001; 229: 141-162. (Pubitemid 32061720)
30. Tommasini SM, Nasser P, Hu B, Jepsen KJ,. Biological co-adaptation of morphological and composition traits contributes to mechanical functionality and skeletal fragility. J Bone Miner Res. 2008; 23: 236-246. (Pubitemid 351160037)
31. Jepsen KJ, Akkus OJ, Majeska RJ, Nadeau JH,. Hierarchical relationship between bone traits and mechanical properties in inbred mice. Mamm Genome. 2003; 14: 97-104. (Pubitemid 36241337)
32. Courtland HW, Demambro V, Maynard J, et al. Sex-specific regulation of body size and bone slenderness by the acid labile subunit. J Bone Miner Res. 2010; 25: 2059-2068.